ワカバヤシ　ムネヒロ   Wakabayashi Munehiro   若林　宗弘    所属   東邦大学  医学部 医学科（大森病院）    職種   助教
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Midline catheter use for cancer patients receiving 5-FU chemotherapy: prospective study of safety and outcomes
掲載誌名	正式名：The Oncologist ISSNコード：1083-7159/1549-490X
掲載区分	国外
出版社	Oxford University Press
巻・号・頁	30(5)
著者・共著者	Tomoki Sakakida, Shinichiro Fukahori, Taro Mizuno, Yasunobu Ishizuka, Munehiro Wakabayashi†, Hiroyuki Kodama, Yukiya Narita, Toshiki Masuishi, Kazunori Honda, Shigenori Kadowaki, Masashi Ando, Kei Muro, Akinobu Ogawa, Chiho Kudo, Isao Oze, Hiroya Taniguchi
発行年月	2025/05/08
概要	Background: Peripheral intravenous 5-fluorouracil (5-FU) administration often causes phlebitis and necessitates catheter replacement, imposing burdens on both patients and healthcare providers. Insertion of a midline catheter (MLC) into the upper arm with tip positioned in the axillary vein may reduce the incidence of phlebitis. This study evaluated the safety and effectiveness of MLC use for continuous 5-FU infusion in cancer patients. Methods: This prospective study included patients with cancer requiring at least 4 days of continuous 5-FU infusion. The primary endpoint was the incidence of phlebitis. Secondary endpoints were the success rate of MLC insertion, complications, and patient-reported outcomes. Results: Of the 61 patients enrolled, 59 were included in the analysis. The median age was 68 years, and primary cancer types were esophageal (51%) and head and neck (46%). The median MLC indwelling duration was 5.5 days (2-28 days). No phlebitis was observed (0%, 95% CI: 0-6.2), achieving the primary endpoint. The insertion success rate was 98.3%, with complications in 6.8%. Over 90% of patients and 80% of healthcare providers reported high satisfaction levels. Conclusion: MLC insertion is a safe and effective approach for continuous 5-FU infusion, eliminating phlebitis, potentially improving patients' quality of life, and reducing healthcare providers' workloads. (ClinicalTrials.gov Identifier: jRCTs042230058).